黄岩，英国帝国理工生物工程博士，PRIORI CAPITAL PTE. LTD. 首席执行官，首都科技发展集团基金合伙人，中关村资本基金合伙人。曾任职于中关村发展集团旗下中关村瞪羚基金和中关村协同创新基金，专注于早期科技项目投资，先后参与了瞪羚一期基金、瞪羚二期基金、中关村常州基金及中关村青田基金的运营与管理。主导投资了天宜上佳（688033）、源杰科技（688498）、北摩高科（002985）、煜邦科技（688597）、泰豪生物、贝瑞森、百邑无忧、演生潮、灵心巧手、清博汇能等公司。2024年与首都科技发展集团联合发起设立衡翼衍至基金并担任基金管理合伙人，同年在新加坡设立 PRIORI CAPITAL 公司并担任 CEO，专注于科技成果转化从 0 到 1 阶段，聚焦影响未来 5-10 年的“硬科技”原始创新，探索国内外具有重大价值的颠覆性、创造性、引领性科技项目的投资与服务。

Dr. HUANG Yan, PhD in Bioengineering from Imperial College London; CEO of PRIORI CAPITAL PTE. LTD.; Fund Partner of Capital Sci-Tech Development Group; Fund Partner of Zhongguancun Capital. Formerly served at Zhongguancun Development Group's subsidiaries, including Zhongguancun Gazelle Fund and Zhongguancun Collaborative Innovation Fund, focusing on early-stage technology project investments. Participated in the operation and management of Gazelle Phase I Fund, Gazelle Phase II Fund, Zhongguancun Changzhou Fund, and Zhongguancun Qingtian Fund. Led investments in companies such as Tianyi Shangjia (688033), Yuanjie Technology (688498), Beimo Hi-Tech (002985), Yubang Technology (688597), Taihao Biotechnology, Berryson, Baiyi Wuyou, Yansheng Tide, Lingxin Qiaoshou, and Qingbo Huineng. In 2024, jointly initiated the establishment of Hengyi Yanzhi Fund with Capital Sci-Tech Development Group and served as the fund management partner, Homo sapiens. In the same year, founded PRIORI CAPITAL in Singapore and assumed the role of CEO, dedicated to the "0 to 1" stage of scientific and technological achievement transformation, focusing on original Deep Tech innovations that will shape the next 5-10 years, and exploring investment and services for disruptive, creative, and leading-edge technology projects of significant value both domestically and internationally.